Gilead Sciences said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell ...

In the last 30 years, HIV rates have gone down, in large part because of the game-changing prescription drug pre-exposure ...

The Indian Patent Office has rejected Viiv Healthcare's patent application for the HIV drug, dolutegravir, after nearly a decade of legal battles. This decision opens the market for generic ...

2024, 7, 8, 2379-2390) Efavirenz is an important drug for treating HIV infection ... were much less abundant in treated mice. That list includes proteins involved in energy metabolism and lipid ...

The antiretroviral drug has been hailed as a potential game-changer in the fight against HIV, with early trials finding the treatment 100 percent effective in preventing HIV infection. With ...

The results generated considerable excitement since a daily pill is nearly 100% effective but compliance is spotty and there is a stigma attached to regularly taking a drug for HIV. But its impact ...

Also that the “cocktail of drugs” used to treat HIV infection and prevent the devasting ... In the late 90’s, Botswana was not in that list. “You knew that if you could get people who ...

The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...

The global HIV drugs market size was valued at $32.8 billion in 2022, and is projected to reach $51.1 billion by 2032, growing at a CAGR of 4.5%. PORTLAND, OR, UNITED STATES, September 26 ...

Professor of medicine and deputy director of the Desmond Tutu HIV Centre at the Institute of Infectious Disease and Molecular Medicine, University of Cape Town A new drug to prevent HIV infection ...

According to the study presented at IDWeek 2024, ibalizumab was chosen more frequently for patients with advanced HIV, demonstrating durability with most subjects remaining on therapy for over two ...

In the U.S., the drug is approved for multi-drug resistant HIV and sold under the brand "Sunlenca" for an annual list price of $42,250 per year. The drugmaker said it will start filing for global ...